Healthcare utilization and direct medical costs of Huntington’s disease among Medicaid beneficiaries in the United States

References

• National Institutes of Health. Huntington’s disease: Hope Through Research. 2020. https://www.ninds.nih.gov/disorders/patient-caregiver-education/hope-through-research/huntingtons-disease-hope-through
   Google Scholar
• Paoli RA, Botturi A, Ciammola A, et al. Neuropsychiatric burden in Huntington’s disease. Brain Sci. 2017;7:67.
   PubMed Web of Science ®Google Scholar
• Exuzides A, Reddy SR, Chang E, et al. Epidemiology of Huntington’s disease in the United States Medicare and Medicaid populations. Neuroepidemiology. 2022;56(3):192–200. doi: 10.1159/000524732.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083–1091. doi: 10.1002/mds.25075.
   PubMed Web of Science ®Google Scholar
• Keum JW, Shin A, Gillis T, et al. The HTT CAG-Expansion mutation determines age at death but not disease duration in Huntington disease. Am J Hum Genet. 2016;98(2):287–298. doi: 10.1016/j.ajhg.2015.12.018.
   PubMed Web of Science ®Google Scholar
• Divino V, DeKoven M, Warner JH, et al. The direct medical costs of Huntington’s disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ. 2013;16(8):1043–1050. doi: 10.3111/13696998.2013.818545.
   PubMedGoogle Scholar
• Dorey J, Tedroff J, Squitieri F, et al. J21 European-Huntington’s disease burden study (EURO-HDB) - Preliminary results for Italy and France. J Neurol Neurosurg Psychiatry. 2010;81(Suppl 1):A45.3–A46. doi: 10.1136/jnnp.2010.222661.21.
   Google Scholar
• Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action: burden of neurological disease. Ann Neurol. 2017;81(4):479–484. doi: 10.1002/ana.24897.
   PubMed Web of Science ®Google Scholar
• Jones C, Busse M, Quinn L, et al. The societal cost of Huntington’s disease: are we underestimating the burden? Eur J Neurol. 2016;23(10):1588–1590. doi: 10.1111/ene.13107.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Divino V, DeKoven M, et al. Interventional differences among Huntington’s disease patients by disease progression in commercial and Medicaid populations. J Huntingtons Dis. 2014;3(4):355–363. doi: 10.3233/JHD-140124.
   PubMedGoogle Scholar
• Sung VW, Iyer RG, Gandhi SK, et al. Retrospective analysis of healthcare resource use, treatment patterns, and treatment-related events in patients with Huntington’s disease-associated chorea initiated on tetrabenazine. J Health Econ Outcomes Res. 2018;6(1):15–24. doi: 10.36469/9779.
   PubMedGoogle Scholar
• Exuzides A, Reddy SR, Chang E, et al. Healthcare utilization and cost burden of Huntington’s disease among Medicare beneficiaries in the United States. J Med Econ. 2021;24(1):1327–1336. doi: 10.1080/13696998.2021.2002579.
   PubMed Web of Science ®Google Scholar
• Exuzides A, To TM, Abbass IM, et al. Healthcare resource utilization and costs in individuals with huntington’s disease by disease stage in a US population. J Med Econ. 2022;25(1):722–729. doi: 10.1080/13696998.2022.2076997.
   PubMed Web of Science ®Google Scholar
• To TM, Exuzides A, Abbass IM, et al. Health care resource utilization and costs among individuals with vs without huntington disease in a US population. J Manag Care Spec Pharm. 2022;28:1228–1239.
   PubMed Web of Science ®Google Scholar
• Mendizabal A, Ngo Vu A-T, Thibault D, et al. Hospitalizations of children with huntington’s disease in the United States. Mov Disord Clin Pract. 2017;4(5):682–688. doi: 10.1002/mdc3.12506.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. Consumer Price Index. U.S. Bureau of Labor Statistics. 2021. https://www.bls.gov/cpi/
   Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi: 10.1371/journal.pmed.0040297.
   PubMed Web of Science ®Google Scholar
• Anderson KE, van Duijn E, Craufurd D, et al. Clinical management of neuropsychiatric symptoms of Huntington disease: expert-Based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders. J Huntingtons Dis. 2018;7(3):355–366. doi: 10.3233/JHD-180293.
   PubMed Web of Science ®Google Scholar
• Ishihara L, Oliveri D, Wild EJ. Neuropsychiatric comorbidities in Huntington’s and Parkinson’s disease: a United States claims database analysis. Ann Clin Transl Neurol. 2021;8(1):126–137. doi: 10.1002/acn3.51252.
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496–502. doi: 10.1176/jnp.17.4.496.
   PubMed Web of Science ®Google Scholar
• Epping EA, Paulsen JS. Depression in the early stages of Huntington disease. Neurodegener Dis Manag. 2011;1(5):407–414. doi: 10.2217/nmt.11.45.
   PubMedGoogle Scholar
• Johnson MO, Frank S, Mendlik M, et al. Utilization of hospice services in a population of patients with Huntington’s disease. J Pain Symptom Manage. 2018;55(2):440–443. doi: 10.1016/j.jpainsymman.2017.09.004.
   PubMed Web of Science ®Google Scholar
• Rodríguez‐Santana I, Mestre T, Squitieri F, et al. Economic burden of Huntington’s disease in Europe and the USA: results from the Huntington’s disease burden of illness study (HDBOI). Euro J of Neurol. 2023;30(4):1109–1117. doi: 10.1111/ene.15645.
   PubMed Web of Science ®Google Scholar
• Dubinsky RM. No going home for hospitalized Huntington’s disease patients. Mov Disord. 2005;20(10):1316–1322. doi: 10.1002/mds.20589.
   PubMed Web of Science ®Google Scholar
• Duncan I, Ahmed T, Dove H, et al. Medicare cost at end of life. Am J Hosp Palliat Care. 2019;36(8):705–710. doi: 10.1177/1049909119836204.
   PubMed Web of Science ®Google Scholar
• Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15. doi: 10.1038/s41531-020-0117-1.
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703–712. doi: 10.18553/jmcp.2010.16.9.703.
   PubMed Web of Science ®Google Scholar
• ResDAC. RIF Data Use Agreement (DUA). ResDAC. 2022. https://resdac.org/request-form/rif-data-use-agreement
   Google Scholar
• ResDAC. Waruiru Mburu. CMS Cell Size Suppression Policy. ResDAC. 2017. https://resdac.org/articles/cms-cell-size-suppression-policy
   Google Scholar
• Chronic Conditions Warehouse. Chronic conditions warehouse virtual research data center: data output review process. West Des Moines, IA: Chronic Conditions Warehouse; 2023.
   Google Scholar